Related Experiment Video
Updated: Jan 2, 2026
Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells
Published on: February 4, 2021
Immune Checkpoint Blockade - How Does It Work in Brain Metastases?
Mihaela Lorger1, Tereza Andreou1, Christopher Fife1
1Institute of Medical Research at St. James's, School of Medicine, University of Leeds, Leeds, United Kingdom.
Abstract:
Immune checkpoints restrain the immune system following its activation and their inhibition unleashes anti-tumor immune responses. Immune checkpoint inhibitors revolutionized the treatment of several cancer types, including melanoma, and immune checkpoint blockade with anti-PD-1 and anti-CTLA-4 antibodies is becoming a frontline therapy in metastatic melanoma. Notably, up to 60% of metastatic melanoma patients develop metastases in the brain. Brain metastases (BrM) are also very common in patients with lung and breast cancer, and occur in ∼20-40% of patients across different cancer types. Metastases in the brain are associated with poor prognosis due to the lack of efficient therapies. In the past, patients with BrM used to be excluded from immune-based clinical trials due to the assumption that such therapies may not work in the context of "immune-specialized" environment in the brain, or may cause harm. However, recent trials in patients with BrM demonstrated safety and intracranial activity of anti-PD-1 and anti-CTLA-4 therapy. We here discuss how immune checkpoint therapy works in BrM, with focus on T cells and the cross-talk between BrM, the immune system, and tumors growing outside the brain. We discuss major open questions in our understanding of what is required for an effective immune checkpoint inhibitor therapy in BrM.
Insights
Immune checkpoint inhibitors are effective against brain metastases (BrM) in melanoma patients. Further research is needed to optimize this therapy for brain tumors and understand its interaction with the immune system.
Area of Science:
- Oncology
- Immunology
- Neuroscience
Background:
- Immune checkpoints regulate immune responses; their inhibition can activate anti-tumor immunity.
- Immune checkpoint inhibitors (ICIs) like anti-PD-1 and anti-CTLA-4 have transformed cancer treatment, including metastatic melanoma.
- Brain metastases (BrM) are common in various cancers and associated with poor prognosis due to limited therapeutic options.
Purpose of the Study:
- To review the mechanisms of immune checkpoint therapy in brain metastases.
- To discuss the safety and efficacy of anti-PD-1 and anti-CTLA-4 therapies in BrM patients.
- To explore the interplay between BrM, the systemic immune system, and extracranial tumors.
Main Methods:
- Review of recent clinical trials and scientific literature on immune checkpoint inhibitors in BrM.
- Analysis of T cell activity and immune responses within the brain microenvironment.
- Discussion of the cross-talk between brain tumors and the peripheral immune system.
Main Results:
- Recent trials show that ICIs (anti-PD-1, anti-CTLA-4) are safe and demonstrate intracranial activity in BrM patients.
- Previously excluded BrM patients now benefit from these immunotherapies.
- Understanding T cell function is crucial for ICI efficacy in the brain.
Conclusions:
- Immune checkpoint blockade is a viable and increasingly utilized therapy for brain metastases.
- Further investigation is required to elucidate the complex interactions influencing ICI effectiveness in BrM.
- Optimizing ICI therapy for BrM necessitates a deeper understanding of the neuro-immune-tumor axis.
Related Concept Videos
01:27Tumor Immunotherapy
00:49The Blood-brain Barrier
02:30Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...